NovavaxRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Novavax (NVAX) reported revenue of $57.00M in Q2 2026, with Licensing, Royalties, and Other its largest revenue segment at 98%.
Q3 2016-Q2 2026
Q3 2016-Q2 2026
NovavaxProtein COVID (Nuvaxovid) and Matrix-M adjuvant. FY 2025 revenue $1.123B, mostly APA settlement. 2026 adjusted revenue guided $230M to $270M with Sanofi leading selected-market commercial.
Novavax (NVAX) is a Biotechnology company. Protein COVID (Nuvaxovid) and Matrix-M adjuvant. FY 2025 revenue $1.123B, mostly APA settlement. 2026 adjusted revenue guided $230M to $270M with Sanofi leading selected-market commercial. It was founded in 1987, is headquartered in Gaithersburg, MD and employs about 1,500 people.
As of 2026-Q2, Novavax's revenue breaks down across Licensing, Royalties, and Other (98%), Royalties and Other (2%). See the revenue-by-segment chart for the full mix.
Track Novavax's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 19, 2026.
Sterling groups Novavax in the Vaccines sector, alongside GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), Moderna (MRNA) and BioNTech (BNTX).
If you are researching Novavax, also look at GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK). You can compare all of them side by side or browse the full Vaccines sector on Sterling.